Trump Administration Puts Freeze on Release of Health Info From Government Agencies

 

Trump Administration Puts Freeze on Release of Health Info From Government Agencies






By Stephanie Brown, HealthDay Reporter

FRIDAY, Jan. 24, 2025 -- President Donald Trump's administration has frozen the release of information from government health agencies.

According to a memo obtained by the Associated Press, the "immediate pause" applies to information released as regulations, guidance, announcements, press releases, social media posts, and website posts because the newly elected administration wants all such information to be reviewed by one of their appointees.

The freeze also affects anything intended to be published in the Federal Register, where the executive branch communicates rules and regulations, and the Morbidity and Mortality Weekly Report, a scientific publication of the U.S. Centers for Disease Control and Prevention.

Acting Secretary of the U.S. Department of Health and Human Services Dorothy Fink told agency staff leaders that the pause will last until Feb. 1, 2025. The directive applies to the CDC, the National Institutes of Health, and the U.S. Food and Drug Administration. Fink added that some exceptions would be made for communications affecting "critical health, safety, environmental, financial, or national security functions."

A former HHS official said Wednesday that it is not unusual for incoming administrations to pause agency communications for review; however, this is usually handled by the president's transition team, and information flow is generally running smoothly by inauguration day.

Associated Press Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.


Comments

Popular posts from this blog

Learn How the NEW Nutrition Facts Label Can Help You Improve Your Health

WHAT PERSONALITY TRAITS IMPACT YOUR ACTIVITY LEVEL?

FDA Approves Generic GLP-1 Medicine For Diabetes Treatment